The Planning Shop International has been acquired by Adelphi Worldwide
The founding shareholders of The Planning Shop International (TPSI) have sold the company to Adelphi Worldwide, part of the Omnicom Group. Financial details have not been disclosed.
TPSI is a specialist pharmaceutical brand strategy agency. The company provides a unique consumer-based insight into every step of the product life cycle.
Adelphi Worldwide, part of the Omnicom Group, is engaged in pharmaceutical consultancy and service provision. Adelphi’s offer spans the lifecycle of pharmaceutical development, with comprehensive services in strategic product development consultancy, health economics and outcomes research, real world disease understanding, marketing research, medical communications and post-meeting brand support services.
Oaklins Cavendish, based in the UK, advised the seller in this transaction.
Talk to the deal team
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn moreNiscon Inc. has been acquired by SGPS ShowRig
Niscon Inc. has been successfully acquired by SGPS ShowRig, a global provider of staging, rigging and automation for live entertainment. The acquisition reinforces SGPS Showrig’s commitment to pushing the boundaries of innovation in the entertainment industry. By adding Niscon’s unique motion-control technology to its portfolio, SGPS Showrig strengthens its ability to deliver cutting-edge, precision-driven solutions.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn more